Evidence map›Paper›PMID 28956830›Full record

ReviewCancers2017

Platelet Integrins in Tumor Metastasis: Do They Represent a Therapeutic Target?

Marion Lavergne, Emily Janus-Bell, Mathieu Schaff, Christian Gachet, Pierre H Mangin

Open access · goldAbstract readReview
In one paragraph

Review in Cancers, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 1 pooled it
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 1 synthesis or guideline pooled it, 93 citations in OpenAlex.

  1. Pooled it
  2. The TAZ-CAMTA1 Fusion Protein Promotes Tumorigenesis via Connective Tissue Growth Factor and Ras-MAPK Signaling in Epithelioid Hemangioendothelioma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Trial
  3. Article
  4. CTC cluster in breast cancer: synergetic metastasis promotion mechanism and transformation path from platelet cloaking to leukocyte escort.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  5. Article
  6. Article
  7. Review
  8. Targeting platelet-tumor cell interactions: a novel approach to cancer therapy.Medical oncology (Northwood, London, England) · 2025
    Review
  9. Article
  10. Article
  11. Conformational response of αStructure (London, England : 1993) · 2025
    Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Fibrinogen and tumors.Frontiers in oncology · 2024
    Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Marion LavergneUniversité de Strasbourg, INSERM, EFS Grand-Est, BPPS UMR-S 949, FMTS, F-67000 Strasbourg, France. marion.lavergne@efs.sante.fr.
Emily Janus-BellUniversité de Strasbourg, INSERM, EFS Grand-Est, BPPS UMR-S 949, FMTS, F-67000 Strasbourg, France. Emily.Janus-Bell@efs.sante.fr.
Mathieu SchaffUniversité de Strasbourg, INSERM, EFS Grand-Est, BPPS UMR-S 949, FMTS, F-67000 Strasbourg, France. mathieu-schaff@outlook.com.
Christian GachetUniversité de Strasbourg, INSERM, EFS Grand-Est, BPPS UMR-S 949, FMTS, F-67000 Strasbourg, France. christian.gachet@efs.sante.fr.ORCID 0000-0003-1303-4210
Pierre H ManginUniversité de Strasbourg, INSERM, EFS Grand-Est, BPPS UMR-S 949, FMTS, F-67000 Strasbourg, France. pierre.mangin@efs.sante.fr.
Inserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Platelets are small anucleated cell fragments that ensure the arrest of bleeding after a vessel wall injury. They are also involved in non-hemostatic function such as development, immunity, inflammation, and in the hematogeneous phase of metastasis. While the role of platelets in tumor metastasis has been recognized for 60 years, the molecular mechanism underlying this process remains largely unclear. Platelets physically and functionally interact with various tumor cells through surface receptors including integrins. Platelets express five integrins at their surface, namely α2β1, α5β1, α6β1, αvβ3, and αIIbβ3, which bind preferentially to collagen, fibronectin, laminin, vitronectin, and fibrinogen, respectively. The main role of platelet integrins is to ensure platelet adhesion and aggregation at sites of vascular injury. Two of these, α6β1 and αIIbβ3, were proposed to participate in platelet-tumor cell interaction and in tumor metastasis. It has also been reported that pharmacological agents targeting both integrins efficiently reduce experimental metastasis, suggesting that platelet integrins may represent new anti-metastatic targets. This review focuses on the role of platelet integrins in tumor metastasis and discusses whether these receptors may represent new potential targets for novel anti-metastatic approaches.

Indexed as

antiplatelet agentscancerhemostasisintegrinsmetastasisplateletsthrombosis

Identifiers

PMID28956830
PMCPMC5664072
OpenAlexW2757120387

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.